Breast Cancer and Trial Updates

The Breast Cancer Channel on VJOncology is supported by Gilead. These supporters have no influence over the production of the content.

View overview page
1:07
NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC
Kevin Kalinsky • 22 Oct 2023
1:04
5-year monarchE results: abemaciclib + ET in high-risk EBC
Kevin Kalinsky • 22 Oct 2023
1:32
The effect of MCED blood tests on patient screening and mental wellbeing
Tom Beer • 22 Oct 2023
3:06
Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histology
Oleg Gluz • 22 Oct 2023
1:36
Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
Kevin Kalinsky • 22 Oct 2023
1:00
Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancer
Sherene Loi • 20 Oct 2023
3:39
CheckMate 7FL: nivo vs PBO in high-risk ER+ HER2- BC with neoadjuvant chemo and adjuvant therapy
Sherene Loi • 20 Oct 2023
1:25
Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer
Kevin Kalinsky • 21 Oct 2023
4:20
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Peter Schmid • 22 Oct 2023
3:22
BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer
Peter Schmid • 22 Oct 2023
0:55
CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancer
Erika Hamilton • 20 Oct 2023
2:01
Safety and tolerability of the vepdegestrant in breast cancer
Erika Hamilton • 20 Oct 2023
1:36
Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
Kevin Kalinsky • 21 Oct 2023
2:15
I-SPY2.2: emerging biomarkers in breast cancer
Denise Wolf • 4 Jun 2023
5:07
What is the role of CDK4/6 inhibitors in early breast cancer?
Michael Gnant • 6 Jun 2023
2:27
NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER2+ breast cancer
Michael Gnant • 8 Jun 2023

The Breast Cancer Channel on VJOncology is supported by Gilead.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Breast Cancer Channel, please contact us.
The content of VJOncology is intended for healthcare professionals